Over the past 12 months, 0 insiders at GLYCOMIMETICS INC filed 0 open-market SEC Form 4 transactions on GLYC: 0 purchases worth $0 and 0 sales worth $0. Insiders have been mixed over this period. The most recent filing was on .
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 8, 24 | L.l.c. SirenTenPercentOwner | SELL | 260.9K | $0.19 | $50K |
| Aug 7, 24 | L.l.c. SirenTenPercentOwner | SELL | 61.5K | $0.18 | $11K |
| Aug 6, 24 | Invus Public Equities Advisors, LlcTenPercentOwner | SELL | 55.7K | $0.18 | $10K |
| Aug 5, 24 | Invus Public Equities Advisors, LlcTenPercentOwner | SELL | 164.5K | $0.19 | $31K |
| Aug 2, 24 | L.l.c. SirenTenPercentOwner | SELL | 286.2K | $0.20 | $57K |
| Aug 1, 24 | L.l.c. SirenTenPercentOwner | SELL | 63.6K | $0.22 | $14K |
| Jul 30, 24 | L.l.c. SirenTenPercentOwner | SELL | 756.8K | $0.22 | $167K |
| Jul 29, 24 | L.l.c. SirenTenPercentOwner | SELL | 363.9K | $0.24 | $87K |
| Jul 26, 24 | L.l.c. SirenTenPercentOwner | SELL | 258.3K | $0.24 | $62K |
| Jun 21, 24 | Edwin RockChief Medical Officer | BUY | 115.0K | $0.27 | $31K |
| Jun 20, 24 | Edwin RockChief Medical Officer | BUY | 190.0K | $0.25 | $48K |
| Jun 18, 24 | Brian M. HahnSVP Finance, CFO | BUY | 17.5K | $0.25 | $4K |
| Sep 22, 23 | Edwin RockChief Medical Officer | BUY | 30.4K | $1.38 | $42K |
| Sep 21, 23 | Edwin RockChief Medical Officer | BUY | 35.0K | $1.38 | $48K |
| May 17, 23 | Brian M. HahnSVP Finance, CFO | SELL | 3.7K | $1.95 | $7K |
| May 10, 23 | Daniel M JuniusDirector | BUY | 30.0K | $1.56 | $47K |
| May 8, 23 | Bruce S JohnsonSVP & Chief Commercial Officer | BUY | 13.5K | $1.57 | $21K |
| Feb 24, 23 | Amaury WittouckTenPercentOwner | BUY | 100.0K | $1.70 | $170K |
| Feb 23, 23 | Artal Group S.a.TenPercentOwner | BUY | 200.0K | $1.75 | $350K |
| Feb 22, 23 | Artal Group S.a.TenPercentOwner | BUY | 150.0K | $1.79 | $269K |
| Feb 21, 23 | Artal Group S.a.TenPercentOwner | BUY | 50.0K | $1.85 | $93K |
| Feb 17, 23 | Amaury WittouckTenPercentOwner | BUY | 200.0K | $1.71 | $342K |
| Feb 16, 23 | Amaury WittouckTenPercentOwner | BUY | 315.3K | $1.68 | $530K |
| Feb 15, 23 | Amaury WittouckTenPercentOwner | BUY | 1.00M | $2.16 | $2.2M |
| Feb 9, 23 | Amaury WittouckTenPercentOwner | BUY | 11.5K | $3.24 | $37K |
| Jan 26, 23 | Scott D SandellTenPercentOwner | SELL | 1.65M | $3.12 | $5.1M |
| Jan 25, 23 | Scott D SandellTenPercentOwner | SELL | 358.4K | $3.26 | $1.2M |
| Jan 5, 23 | Scott D SandellTenPercentOwner | SELL | 39.2K | $2.76 | $108K |
| Jan 4, 23 | Scott D SandellTenPercentOwner | SELL | 56.1K | $2.91 | $163K |
| Jan 3, 23 | Scott D SandellTenPercentOwner | SELL | 96.1K | $2.99 | $287K |
| Dec 30, 22 | Scott D SandellTenPercentOwner | SELL | 66.7K | $3.02 | $201K |
| Dec 22, 22 | Edwin RockChief Medical Officer | BUY | 110.0K | $2.25 | $248K |
| Nov 17, 22 | Daniel M JuniusDirector | BUY | 20.0K | $1.87 | $37K |
| Nov 15, 22 | Edwin RockChief Medical Officer | BUY | 100.0K | $1.66 | $166K |
| Nov 14, 22 | Edwin RockChief Medical Officer | BUY | 100.0K | $1.43 | $143K |
| Nov 11, 22 | Armand GirardSVP, Chief Business Officer | BUY | 6.5K | $1.05 | $7K |
| Nov 11, 22 | Brian M. HahnSVP Finance, CFO | BUY | 20.0K | $1.06 | $21K |
| Nov 11, 22 | John L. MagnaniSVP of Research, CSO | BUY | 45.0K | $1.17 | $53K |
| Nov 11, 22 | Timothy R PearsonDirector | BUY | 19.4K | $1.29 | $25K |
| Nov 11, 22 | Harout SemerjianChief Executive Officer | BUY | 25.0K | $1.29 | $32K |
| Mar 9, 22 | Armand GirardSVP, Chief Business Officer | SELL | 2.3K | $1.09 | $3K |
| Mar 9, 22 | Brian M. HahnSVP Finance, CFO | SELL | 2.9K | $1.09 | $3K |
| Mar 9, 22 | John L. MagnaniSVP of Research, CSO | SELL | 3.2K | $1.09 | $4K |
| Nov 16, 21 | Patricia S AndrewsDirector | BUY | 40.0K | $2.05 | $82K |
Over the past 12 months, insiders at GLYCOMIMETICS INC filed 0 open-market purchases worth $0 and 0 sales worth $0 on GLYC, which makes them mixed over the period. The most recent Form 4 was filed on .
The largest recent open-market GLYC insider purchase in our data was $2.2M by Amaury Wittouck, TenPercentOwner, filed on Feb 15, 23.
0 different insiders at GLYCOMIMETICS INC filed open-market SEC Form 4 transactions on GLYC over the last 12 months.
InsiderTape plots every GLYC insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every GLYCOMIMETICS INC insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →